cobicistat (stribild) Report issue

Small molecule Approved FDA Fast Track FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cobicistat (GS-9350) is a potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes. Cobicistat is a pharmacokinetic booster of several antiretrovirals. TYBOST (cobicistat) is indicated to increase systemic exposure of atazanavir or darunavir in combination with other antiretroviral agents in the treatment of HIV-1 infection.   NCATS

Chemistry

  • SMILES: CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)=CS1
  • InChIKey: ZCIGNRJZKPOIKD-CQXVEOKZSA-N
  • Mol. Mass: 776.023
  • ALogP: 6.0
  • ChEMBL Molecule:
    cobicistat  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$5.6953 - $5.8400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( atazanavir (reyataz), cobicistat (stribild) )
|
( emtricitabine (emtriva), tenofovir alafenamide (genvoya), cobicistat (stribild), elvitegravir (vitekta) - other name: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide )
|
( darunavir (prezista), cobicistat (stribild) )
|
( tenofovir (viread), emtricitabine (emtriva), cobicistat (stribild), elvitegravir (vitekta) - other name: cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate )
|
( emtricitabine (emtriva), darunavir (prezista), tenofovir alafenamide (genvoya), cobicistat (stribild) )

Alternative names

1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate | atazanavir sulfate / cobicistat | cobicistat | cobicistat on silicon dioxide | combicistat | darunavir / cobicistat | darunavir / cobicistat / emtricitabine / tenofovir alafenamide | elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide | elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate | gs 9350 | stribild | tybost

Organizations (85)

Research & Development (84)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (31)

Approved Indications (2)


 

HIV Infections

Infections

Experimental Indications - Clinical Trial Phases 1-4 (31)


 

Acquired Immunodeficiency Syndrome (Phase 4)

AIDS Dementia Complex (Phase 4)

Antiretroviral Therapy, Highly Active (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Cognition Disorders (Phase 4)

Coronavirus (Phase 3)

Cytochrome P-450 CYP3A Inhibitors (Phase 1)

Drug Interactions (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 1/Phase 2)

Healthy Volunteers (Phase 4)

Hepatitis B (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV Infections ()

Infections ()

Insulin Resistance (Phase 1)

Latent Tuberculosis (Phase 1)

Leukemia, Myeloid, Acute (Phase 2)

Malaria (Phase 1)

Mitochondrial Diseases (Phase 1/Phase 2)

Neoplasms (Phase 4)

Obesity (Phase 4)

Pancreatic Neoplasms (Phase 1)

Patient Compliance (Phase 4)

Pharmacokinetics (Phase 1)

Pneumonia, Pneumocystis (Phase 3)

Pregnancy (Phase 3)

Sleep Wake Disorders (Phase 4)

Tuberculosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 123
  • # of Trial Organizations: 84

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue